Aikaterini Eleftheriadou1, Scott Williams1, Sarah Nevitt2, Emily Brown1, Rebecca Roylance3, John P H Wilding4, Daniel J Cuthbertson4, Uazman Alam5,6,7. 1. Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. 2. Department of Biostatistics, University of Liverpool, Liverpool, UK. 3. Edge Hill University Library, Aintree University Hospital NHS Foundation Trust, Liverpool, UK. 4. Obesity and Endocrinology Research, Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. 5. Division of Diabetes, Endocrinology and Gastroenterology, Institute of Human Development, University of Manchester, Manchester, UK. uazman.alam@liverpool.ac.uk. 6. Pain Research Institute and Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool and Aintree University Hospital NHS Foundation Trust, Liverpool, UK. uazman.alam@liverpool.ac.uk. 7. Department of Diabetes and Endocrinology, Liverpool University Hospital NHS Trust, Liverpool, UK. uazman.alam@liverpool.ac.uk.
Abstract
AIMS/HYPOTHESIS: Cardiac autonomic neuropathy (CAN) is independently associated with silent myocardial ischaemia, major cardiovascular events, myocardial dysfunction and cardiovascular mortality. Several studies have highlighted the increased prevalence of CAN in prediabetes (impaired glucose tolerance and/or impaired fasting glucose). Considering the exponential rise of prediabetes, we aimed to determine the prevalence of CAN through a systematic literature review. METHODS: This systematic review was registered with PROSPERO (CRD42019125447). An electronic literature search was performed using MEDLINE, EMBASE, PubMed, Web of Science, Scopus and Cochrane databases. Published full text, English language articles that provide CAN prevalence data of studies in individuals with prediabetes and aged over 18 years were included. Prevalence data for normal glucose tolerance and diabetes were also extracted from the selected articles, if present. All articles were screened by two independent reviewers using a priori criteria. Methodological quality and risk of bias were evaluated using a critical appraisal tool. RESULTS: Database searches found 4500 articles; subsequently, 199 full text articles were screened, 11 of which fulfilled the inclusion criteria (4431 total participants, 1730 people with prediabetes, 1999 people with normal glucose tolerance [NGT] and 702 people with predominantly type 2 diabetes). Six of the selected studies reported definite CAN prevalence data (9-39%). Only a single large population-based study by Ziegler et al (KORA S4 study, 1332 participants) determined definite CAN based on two or more positive autonomic function tests (AFTs), with a mean prevalence of 9% in all prediabetes groups (isolated impaired glucose tolerance 5.9%; isolated impaired fasting glucose 8.1%; impaired fasting glucose plus impaired glucose tolerance 11.4%), which was higher than NGT (4.5%). This study is most likely to provide a reliable population-specific estimate of CAN in prediabetes. There was a higher than expected prevalence of CAN in prediabetes (9-38%) when compared with normal glucose tolerance (0-18%) within the same studies (n = 8). There was a wide prevalence of possible CAN based on one positive AFT (n = 5). There was heterogeneity between the studies with variations in the definition of CAN, methodology and characteristics of the populations, which likely contributed to the diversity of prevalence estimates. The overall risk of bias was low. CONCLUSIONS/ INTERPRETATION: There is a higher than expected prevalence of CAN in prediabetes. Early detection of CAN in prediabetes through population screening needs careful consideration in view of the excess morbidity and mortality risk associated with this condition. Graphical abstract.
AIMS/HYPOTHESIS: Cardiac autonomic neuropathy (CAN) is independently associated with silent myocardial ischaemia, major cardiovascular events, myocardial dysfunction and cardiovascular mortality. Several studies have highlighted the increased prevalence of CAN in prediabetes (impaired glucose tolerance and/or impaired fasting glucose). Considering the exponential rise of prediabetes, we aimed to determine the prevalence of CAN through a systematic literature review. METHODS: This systematic review was registered with PROSPERO (CRD42019125447). An electronic literature search was performed using MEDLINE, EMBASE, PubMed, Web of Science, Scopus and Cochrane databases. Published full text, English language articles that provide CAN prevalence data of studies in individuals with prediabetes and aged over 18 years were included. Prevalence data for normal glucose tolerance and diabetes were also extracted from the selected articles, if present. All articles were screened by two independent reviewers using a priori criteria. Methodological quality and risk of bias were evaluated using a critical appraisal tool. RESULTS: Database searches found 4500 articles; subsequently, 199 full text articles were screened, 11 of which fulfilled the inclusion criteria (4431 total participants, 1730 people with prediabetes, 1999 people with normal glucose tolerance [NGT] and 702 people with predominantly type 2 diabetes). Six of the selected studies reported definite CAN prevalence data (9-39%). Only a single large population-based study by Ziegler et al (KORA S4 study, 1332 participants) determined definite CAN based on two or more positive autonomic function tests (AFTs), with a mean prevalence of 9% in all prediabetes groups (isolated impaired glucose tolerance 5.9%; isolated impaired fasting glucose 8.1%; impaired fasting glucose plus impaired glucose tolerance 11.4%), which was higher than NGT (4.5%). This study is most likely to provide a reliable population-specific estimate of CAN in prediabetes. There was a higher than expected prevalence of CAN in prediabetes (9-38%) when compared with normal glucose tolerance (0-18%) within the same studies (n = 8). There was a wide prevalence of possible CAN based on one positive AFT (n = 5). There was heterogeneity between the studies with variations in the definition of CAN, methodology and characteristics of the populations, which likely contributed to the diversity of prevalence estimates. The overall risk of bias was low. CONCLUSIONS/ INTERPRETATION: There is a higher than expected prevalence of CAN in prediabetes. Early detection of CAN in prediabetes through population screening needs careful consideration in view of the excess morbidity and mortality risk associated with this condition. Graphical abstract.
Authors: Eva M Lonn; Sherryn Rambihar; Peggy Gao; Florian F Custodis; Karen Sliwa; Koon K Teo; Salim Yusuf; Michael Böhm Journal: Clin Res Cardiol Date: 2013-12-20 Impact factor: 5.460
Authors: J G Canto; M G Shlipak; W J Rogers; J A Malmgren; P D Frederick; C T Lambrew; J P Ornato; H V Barron; C I Kiefe Journal: JAMA Date: 2000-06-28 Impact factor: 56.272
Authors: Emilie H Zobel; Philip Hasbak; Signe A Winther; Christian Stevns Hansen; Jesper Fleischer; Bernt J von Scholten; Lene Holmvang; Andreas Kjaer; Peter Rossing; Tine W Hansen Journal: Diabetes Date: 2019-03-12 Impact factor: 9.461
Authors: Akif Serhat Balcioğlu; Sinan Akinci; Davran Çiçek; Halil Olcay Eldem; Ali Çoner; Uğur Abbas Bal; Haldun Müderrisoğlu Journal: Diabetes Metab Syndr Date: 2015-10-03
Authors: Lucianne Righeti Monteiro Tannus; Karla Rezende Guerra Drummond; Eliete Leão da Silva Clemente; Maria de Fátima Bevilacqua da Matta; Marilia Brito Gomes Journal: Front Endocrinol (Lausanne) Date: 2014-11-25 Impact factor: 5.555
Authors: Omar Asghar; Ioannis N Petropoulos; Uazman Alam; Wendy Jones; Maria Jeziorska; Andrew Marshall; Georgios Ponirakis; Hassan Fadavi; Andrew J M Boulton; Mitra Tavakoli; Rayaz A Malik Journal: Diabetes Care Date: 2014-06-26 Impact factor: 19.112
Authors: Varo Kirthi; Anugraha Perumbalath; Emily Brown; Sarah Nevitt; Ioannis N Petropoulos; Jamie Burgess; Rebecca Roylance; Daniel J Cuthbertson; Timothy L Jackson; Rayaz A Malik; Uazman Alam Journal: BMJ Open Diabetes Res Care Date: 2021-05
Authors: Giulia Ferrannini; Dirk De Bacquer; Pieter Vynckier; Guy De Backer; Viveca Gyberg; Kornelia Kotseva; Linda Mellbin; Anna Norhammar; Jaakko Tuomilehto; David Wood; Lars Rydén Journal: Cardiovasc Diabetol Date: 2021-02-11 Impact factor: 9.951
Authors: Hebatalla Said Ali; Mariam Sameh Boshra; Sara H A Agwa; Mohamed S Abdel Hakeem; Mahmoud Shawky El Meteini; Marwa Matboli Journal: Biomolecules Date: 2022-09-02